Brokerages forecast that Integra Lifesciences Holdings Corp (NASDAQ:IART) will announce earnings per share of $0.62 for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for Integra Lifesciences’ earnings. The highest EPS estimate is $0.64 and the lowest is $0.59. Integra Lifesciences reported earnings per share of $0.64 in the same quarter last year, which would indicate a negative year-over-year growth rate of 3.1%. The company is scheduled to report its next earnings report on Tuesday, February 26th.
On average, analysts expect that Integra Lifesciences will report full-year earnings of $2.39 per share for the current fiscal year, with EPS estimates ranging from $2.36 to $2.41. For the next fiscal year, analysts forecast that the company will report earnings of $2.66 per share, with EPS estimates ranging from $2.61 to $2.71. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Integra Lifesciences.
Integra Lifesciences (NASDAQ:IART) last released its earnings results on Wednesday, October 31st. The life sciences company reported $0.59 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.59. Integra Lifesciences had a net margin of 5.49% and a return on equity of 16.99%. The company had revenue of $365.85 million for the quarter, compared to analyst estimates of $367.89 million. During the same quarter last year, the firm earned $0.45 EPS. The firm’s quarterly revenue was up 31.2% compared to the same quarter last year.
A number of equities research analysts have issued reports on IART shares. Zacks Investment Research raised shares of Integra Lifesciences from a “sell” rating to a “hold” rating in a report on Wednesday. BidaskClub lowered shares of Integra Lifesciences from a “buy” rating to a “hold” rating in a report on Tuesday. Morgan Stanley set a $68.00 price target on shares of Integra Lifesciences and gave the stock a “hold” rating in a report on Thursday, October 11th. Oppenheimer reissued a “buy” rating on shares of Integra Lifesciences in a report on Tuesday, October 2nd. Finally, UBS Group started coverage on shares of Integra Lifesciences in a report on Tuesday, November 27th. They issued a “neutral” rating and a $58.00 price target on the stock. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $61.62.
In other news, major shareholder Richard E. Caruso sold 46,676 shares of the firm’s stock in a transaction dated Wednesday, October 17th. The shares were sold at an average price of $63.19, for a total value of $2,949,456.44. Following the completion of the sale, the insider now directly owns 134,134 shares of the company’s stock, valued at approximately $8,475,927.46. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Barbara B. Hill bought 3,705 shares of the company’s stock in a transaction dated Monday, November 5th. The stock was bought at an average cost of $53.90 per share, with a total value of $199,699.50. Following the completion of the transaction, the director now owns 63,381 shares in the company, valued at approximately $3,416,235.90. The disclosure for this purchase can be found here. Company insiders own 5.10% of the company’s stock.
Several large investors have recently bought and sold shares of the company. Commonwealth Equity Services LLC lifted its position in shares of Integra Lifesciences by 8.8% in the 3rd quarter. Commonwealth Equity Services LLC now owns 11,913 shares of the life sciences company’s stock worth $784,000 after purchasing an additional 965 shares during the period. First National Bank of Omaha lifted its position in shares of Integra Lifesciences by 2.8% in the 3rd quarter. First National Bank of Omaha now owns 39,980 shares of the life sciences company’s stock worth $2,633,000 after purchasing an additional 1,076 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of Integra Lifesciences by 20.1% in the 3rd quarter. Tower Research Capital LLC TRC now owns 6,904 shares of the life sciences company’s stock worth $455,000 after purchasing an additional 1,156 shares during the period. Arizona State Retirement System lifted its position in shares of Integra Lifesciences by 2.4% in the 3rd quarter. Arizona State Retirement System now owns 50,172 shares of the life sciences company’s stock worth $3,305,000 after purchasing an additional 1,196 shares during the period. Finally, Riverhead Capital Management LLC lifted its position in shares of Integra Lifesciences by 35.0% in the 3rd quarter. Riverhead Capital Management LLC now owns 4,626 shares of the life sciences company’s stock worth $305,000 after purchasing an additional 1,200 shares during the period. 85.94% of the stock is owned by hedge funds and other institutional investors.
IART stock opened at $49.96 on Friday. The company has a debt-to-equity ratio of 1.04, a quick ratio of 2.08 and a current ratio of 3.20. Integra Lifesciences has a 52 week low of $45.96 and a 52 week high of $67.50. The firm has a market cap of $4.34 billion, a P/E ratio of 25.75, a price-to-earnings-growth ratio of 1.59 and a beta of 0.76.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Featured Article: What does EPS mean?
Get a free copy of the Zacks research report on Integra Lifesciences (IART)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.